切换至 "中华医学电子期刊资源库"

中华肺部疾病杂志(电子版) ›› 2022, Vol. 15 ›› Issue (06) : 904 -907. doi: 10.3877/cma.j.issn.1674-6902.2022.06.039

综述

吸入药物在慢性阻塞性肺疾病和肺癌中的应用及进展
王冠1, 徐兴祥2,()   
  1. 1. 116000 辽宁,大连医科大学呼吸内科
    2. 225000 江苏,苏北人民医院 呼吸与危重症医学科
  • 收稿日期:2022-01-18 出版日期:2022-12-25
  • 通信作者: 徐兴祥

Application and progress of inhaled drugs in chronic obstructive pulmonary disease and lung cancer

Guan Wang1, Xingxiang Xu2()   

  • Received:2022-01-18 Published:2022-12-25
  • Corresponding author: Xingxiang Xu
引用本文:

王冠, 徐兴祥. 吸入药物在慢性阻塞性肺疾病和肺癌中的应用及进展[J]. 中华肺部疾病杂志(电子版), 2022, 15(06): 904-907.

Guan Wang, Xingxiang Xu. Application and progress of inhaled drugs in chronic obstructive pulmonary disease and lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(06): 904-907.

慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)是一种以气流受限为特征的进行性肺疾病,是全球第三大慢性疾病和死亡原因,慢性呼吸道疾病占全球DALY(伤残调整寿命年)的4.7%,其中COPD约占三分之二[1,2]。肺癌是起源于支气管黏膜或腺体的恶性肿瘤,在全球范围内,肺癌是最常见的癌症(约占男女癌症总数的11%),也是世界上与癌症有关的死亡率的主要原因(约占癌症相关死亡率的18%左右)[3]。肺癌的预后差,5年生存率约仅为15%,占所有癌症死亡的13%,每年死亡例数超过140万例,预计到2030年,肺癌死亡例数将增加到每年1 000万例[4,5]。COPD与肺癌之间存在密切联系,COPD是肺癌的危险因素[6,7]。与非COPD患者相比,COPD患者发生肺癌的风险可增加2~4倍,COPD合并肺癌的患者疾病进展迅速,预后较差,考虑与肺癌和COPD的共同危险因素、肺功能受损等相关。部分早期肺癌合并COPD患者,因肺功能差,不能耐受手术,导致疾病进展,对于这部分患者可通过吸入药物改善肺功能,进而达到手术的目的,同时减少术后并发症。同时有研究显示,炎症因子可以增强癌细胞的进展能力[8,9,10]。通过吸入药物抗炎、改善肺功能在肺癌合并COPD患者治疗中十分重要。本文主要综述吸入药物在COPD合并肺癌患者中的作用及吸入药物中的应用情况。

表1 吸入装置
1
Christopher JLM, Theo V, Rafael L, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2197-2223.
2
陈华萍,甘志新,刘 刚,等. 慢性阻塞性肺疾病的合并症/并发症的发病率和病死率分析[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 417-421.
3
Freddie B, Jacques F, Isabelle S, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
4
Jacques F, Isabelle S, Rajesh D, et al.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-386.
5
Ferlay J, Ward E, Forman D, et al. Global cancer statistics[J]. CA cancer J Clin, 2011, 61(2): 69-90.
6
廖 晨,余祖滨,张 萍,等. 慢性阻塞性肺疾病合并肺癌122例临床特征分析[J/CD]. 中华肺部疾病杂志(电子版), 2015, 8(1): 30-34.
7
任成山,白 莉,钱桂生. 慢性阻塞性肺疾病合并肺癌临床特征及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2015, 8(2): 137-142.
8
Markus FN, Susetta F. The emerging role of T cell cytokines in non-small cell lung cancer[J]. Cytokine growth factor Rev, 2012, 23(6): 315-322.
9
Vasilena G, Wang HW, Bedrick BG, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion[J]. Genes dev, 2010, 24(3): 241-255.
10
Norimasa I, Yoshimasa S, Yuji T, et al. Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer[J]. Anticancer Rese, 2005, 25: 2027-2031.
11
Houghton AM. Mechanistic links between COPD and lung cancer[J]. Nat rev Cancer, 2013, 13(4): 233-245.
12
Wang P, Zhu M, Zhang D, et al. The relationship between chronic obstructive pulmonary disease and non-small cell lung cancer in the elderly[J]. Cancer Med, 2019, 8(9): 4124-4134.
13
Durham A, Adcock I. The relationship between COPD and lung cancer [J]. Lung cancer (Amsterdam, Netherlands), 2015, 90(2): 121-127.
14
Stacy R, Keenan AH, Malcolm MDeCamp Jr, et al. Lung cancer in chronic obstructive pulmonary disease: enhancing surgical options and outcomes[J]. Am J Respir Crit Care Med, 2011, 183(9): 1138-1146.
15
Irene, Heijink, Vijayanand, et al. Pathological changes in the COPD lung mesenchyme-novel lessons learned from in vitro and in vivo studies[J]. Pulm pharmacol Ther, 2014, 29(2): 121-128.
16
Robert PY, Raewyn JH, Gregory DG, et al. Genetic evidence linking lung cancer and COPD: a new perspective[J]. Appl Clin Genet, 2011, 4: 99-111.
17
Houghton MG, Mouded M, Shapiro SD. Common origins of lung cancer and COPD[J]. Nat Med, 2008, 14(10): 1023-1024.
18
Rama I, Griny JM. Malignancy after renal transplantation: the role of immunosuppression[J]. Nat Rev Nephrol, 2010, 6(9): 511-519.
19
Rayleen VB, Ian AY, Annalese BTS, et al. Epigenetics of lung cancer[J]. Respirology , 2006, 11(4): 355-365.
20
Wasswa-Kintu S, Gan WQ, Man SFP, et al. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis[J]. Thorax, 2005, 60(7): 570-575.
21
Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history[J]. Eur Respir J, 2009, 34(2): 380-386.
22
Robert PY, Duan Fh, Caroline C, et al. Airflow limitation and histology shift in the National lung screening trial. The NLST-ACRIN cohort substudy[J]. Am J Respir Crit Care Med, 2015, 192(9): 1060-1067.
23
Zhai R, Yu X, Wei Y, et al. Smoking and smoking cessation in relation to the development of co-existing non-small cell lung cancer with chronic obstructive pulmonary disease[J]. Int J Cancer, 2014, 134(4): 961-970.
24
Edwar BK, Noone AM, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer[J]. Cancer, 2014, 120(9): 1290-1314.
25
Sekine Y, Behnia M, Fujisawa T. Impact of COPD on pulmonary complications and on long-term survival of patients undergoing surgery for NSCLC[J]. Lung cancer, 2002, 37(1): 95-101.
26
Loganathan RS, Stover DE, Shi W, et al. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer[J]. Chest, 2006, 129(5): 1305-1312.
27
Wang DC, Lin S, Zhu Z, et al. Genomic mechanisms of transformation from chronic obstructive pulmonary disease to lung cancer[J]. Semin Cancer Biol, 2017, 42: 52-59.
28
Camilo NC, Kato S, Cunha I, et al. Diagnosis of pulmonary malignancy after hospitalization for pneumonia[J]. Am J Med, 2010, 123(1): 66-71.
29
Yasuo S, Hideki K, Eitetsu K, et al. Early detection of COPD is important for lung cancer surveillance[J]. Eur Respir J, 2012, 39(5): 1230-1240.
30
The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med, 2011, 365(5): 395-409.
31
Giulia V, Patrick M, Massimo B, et al. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study[J]. Ann intern Med, 2012, 157(11): 76-84.
32
Robert P Young, Raewyn J Hopkins. Estimating overdiagnosis of lung cancer[J]. Ann Intern Med, 2013, 158(8): 635.
33
Bernd L, Joan BS, Michael S, et al. Determinants of underdiagnosis of COPD in national and international surveys[J]. Chest, 2015, 148(4): 971-985.
34
Carlos HM, David MM, Fabian AJ, et al. Undiagnosed obstructive lung disease in the united states. Associated factors and long-term mortality[J]. Ann Am Thorac So, 2015, 12(12): 1788-1795.
35
Andrea SG, Jeremiah H, Kenneth RC, et al. Factors associated with undiagnosed and overdiagnosed COPD[J]. Eur Respir J, 2016, 48(2): 561-564.
36
Collins BF, Ramenofsky DA, David H, et al. The association of weight with the detection of airflow obstruction and inhaled treatment among patients with a clinical diagnosis of COPD[J]. Chest, 2014, 146(6): 1513-1520.
37
Nicholas AZ, Guy BM, Oshana H, et al. Predictors of accuracy of diagnosis of chronic obstructive pulmonary disease in general practice[J]. Med J Aust, 2011, 195(4): 168-171.
38
Juan P de T, Gorka B, Juan PW, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest[J]. Chest, 2007, 132(6): 1932-1938.
39
Robert PY, Raewyn JH. Targeted CT image screening and its effect on lung cancer detection rate[J]. Chest, 2013, 144(4): 1419-1420.
40
Bartolome RC. Chronic obstructive pulmonary disease and lung cancer:common pathogenesis, shared clinical challenges[J]. Proc Am Thorac Soc, 2012, 9(2): 74-79.
41
Juan P de-T, Ciro C, Jose MM, et al. Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study[J]. Respir Med, 2013, 107(5): 702-707.
42
Robert PY, Raewyn JH. Diagnosing COPD and targeted lung cancer screening[J]. Eur Res J, 2012, 40(4): 1063-1064.
43
Victor AK, Joan S, George V, et al. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database[J]. Prim Care Respir J, 2010, 19(1): 57-61.
44
Liu SF, Kuo HC, Lin MC, et al. Inhaled corticosteroids have a protective effect against lung cancer in female patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study[J]. Oncotarget, 2017, 8(18): 29711-29721.
45
Adam JNR, Natalie McC, Carlo AM, et al. Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review[J]. Respirology, 2017, 22(1): 61-70.
46
Victor AK, Leonardo MF, Kourtney JD, et al. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking[J]. Respir Med, 2009, 103(1): 85-90.
47
Lu WY, Pawan S, Mathew SE, et al. Inhaled corticosteroids attenuate epithelial mesenchymal transition: implications for COPD and lung cancer prophylaxis[J]. Eur Res J, 2019, 54(1): 1900778.
48
Yao RS, Wang Y, William JL, et al. Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions[J]. Oncogene, 2004, 23(46): 7746-7752.
49
Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease[J]. Thorax, 2005, 60(12): 992-997.
50
Naozumi H, Asuka M, Yu O, et al. Clinical impact of prevalence and severity of COPD on the decision-making process for therapeutic management of lung cancer patients[J]. BMC Pulm Med, 2014, 14: 14.
51
Alessandro B, Anthony WK, Kenneth IB, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013, 143: e166S-e190S.
52
Brunelli A, Charloux A, Bolliger CT, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)[J]. Eur Respir J, 2009, 34(1): 17-41.
53
Claus FV, Gerard JC, Fernando JM, et al.Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary [J]. Am J Respir Crit Care Med, 2017, 195(5): 557-582.
54
Ian AY, Juliet LB, Johnson G, et al. COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update[J]. Med J Aust, 2017, 207(10): 436-442.
55
Kyoshiro T, Jitsuo U, Tatsuya I, et al. Preoperative management using inhalation therapy for pulmonary complications in lung cancer patients with chronic obstructive pulmonary disease[J]. Gen Thorac Cardiovasc Surg, 2017, 65(7): 388-391.
56
Takashi N, Masayoshi I, Kazuhiro Y, et al. Inhaled tiotropium to prevent postoperative cardiopulmonary complications in patients with newly diagnosed chronic obstructive pulmonary disease requiring lung cancer surgery[J]. Surg Today, 2014, 44(2): 285-290.
57
Andrea SM, Marco B, Vincenzo C, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control[J]. Respir Med, 2011, 105(6): 930-938.
58
Mariëlle EACB, Joaquin S, Mark LL, et al. The 2ADMIT series-issues in inhalation therapy. 2. Improving technique and clinical effectiveness[J]. Prim Care Respir J, 2009, 18(2): 76-82.
59
高 怡,黄思琪,周伟良,等. 慢性阻塞性肺疾病患者使用干粉吸入器的吸气能力[J]. 广东医学2014, 35(19): 3002-3006.
60
Theerasuk K, Supattra K, Prapaporn P. Peak inspiratory flow rate measurement by using In-Check DIAL for the different inhaler devices in elderly with obstructive airway diseases[J]. J Asthma Allergy, 2017, 10: 17-21.
[1] 樊逸隽, 杨枫, 王玮, 殷鹤英, 刘俊. 喉前淋巴结转移对甲状腺乳头状癌诊疗价值的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(04): 306-310.
[2] 梁开地, 缑文斌, 莫居容. 肺癌组织中细胞角蛋白18的表达及与预后的相关性[J]. 中华肺部疾病杂志(电子版), 2023, 16(05): 688-690.
[3] 周杉京, 诸葛金科, 王芳芳. 补肺活血胶囊对COPD患者cCor、ALD、Ang-Ⅱ的影响[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 517-519.
[4] 吴庆华, 冒勇, 闫效坤. AECOPD并发AKI的危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 529-531.
[5] 芦丹, 杨硕, 刘旭. VEGF、HMGB1、hs-CRP/Alb在AECOPD伴呼吸衰竭中的变化及预后分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 532-534.
[6] 蒙姣姣, 胡刚, 欧阳涣堃. 肺癌术前淋巴结转移及MWA手术效果预测分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 547-549.
[7] 熊锋, 娄建丽. 慢性阻塞性肺疾病急性加重期预后的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 550-553.
[8] 王庆, 张红联, 吴志勇. COPD合并多重耐药菌肺部感染预后危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 557-559.
[9] 林静, 陈芳, 刘小霞. COPD患者认知功能障碍影响因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 569-571.
[10] 张七妹, 麦宜准, 蒋浩波. 喘可治对慢性阻塞性肺疾病缓解期的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 578-580.
[11] 张林, 刘芳, 赵静, 刘勇, 周青. 远程康复在慢性阻塞性肺疾病患者肺康复中的研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 601-604.
[12] 唐英俊, 李华娟, 王赛妮, 徐旺, 刘峰, 李羲, 郝新宝, 黄华萍. 人脐带间充质干细胞治疗COPD小鼠及机制分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 476-480.
[13] 徐丽玲, 卢玉宝, 赵彦, 任利, 李姝艺, 符娟, 康玲, 汪青松, 尤再春. COPD管理云平台的构建及临床应用[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 481-484.
[14] 蓝冰, 王怀明, 王辉, 马波. 局部晚期结肠癌膀胱浸润的研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 505-511.
[15] 吴一菡, 雷章, 卢宏达. MUC16/CA125在良恶性肿瘤诊治中的作用及其研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(05): 591-595.
阅读次数
全文


摘要